Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | MITF | O75030 | 2/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640709 | 1.00 | KDM4E (0.59) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL283337 | 1.00 | KDM4E (0.59) | KDM4EPKMNPC1RAB9AMITF | |
| Hydrochloric Acid SCHEMBL29620972 | 0.98 | KDM4E (0.57) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL18653617 | 0.84 | NPC1 (0.54) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL834329 | 0.83 | KDM4E (0.54) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL1428592 | 0.83 | KDM4E (0.54) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL12560610 | 0.83 | KDM4E (0.54) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL24170743 | 0.81 | PKM (0.51) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL2931559 | 0.81 | LMNA (0.54) | KDM4EPKMNPC1RAB9AMITF | |
| SCHEMBL22872697 | 0.81 | LMNA (0.54) | KDM4EPKMNPC1RAB9AMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118146449-A | Pickering high internal phase molecularly imprinted polymer stabilized by metal organic framework material, preparation and application thereof | 南开大学 | 2024-06-07 | — | — | CN | claimed |
| CN-111607055-B | High molecular weight polyurethane based on dynamic reversible covalent bond and preparation method and application thereof | 中国科学院化学研究所 | 2021-07-16 | — | — | CN | claimed |
| WO-2025262596-A1 | METHODS OF MAKING OSIVELOTOR | PFIZER INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| CN-115697979-B | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025121401-A1 | PYRAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | 日産化学株式会社 | 2025-06-12 | — | — | WO | disclosed |
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| WO-2025061707-A1 | SYNTHESIS OF SULFOXIMINES CONTAINING A BENZIMIDAZOLE MOIETY | SYNGENTA CROP PROTECTION AG (CH) | 2025-03-27 | — | — | WO | disclosed |
| EP-4139287-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-5369113-A | Certain 2,3-diphenyl-2-(1,2,4-oxadiazol-5-yl)tropanes useful as dopamide reuptake inhibitors | NEUROSEARCH A/S (DK) | 1994-11-29 | — | — | US | disclosed |
| EP-0616807-A1 | Benzimidazole useful in the treatment of central nervous system disorders | NEUROSEARCH A/S (DK) | 1994-09-28 | — | — | EP | disclosed |
| EP-0604352-A2 | Aryl substituted heterocyclic compounds | NEUROSEARCH A/S (DK) | 1994-06-29 | — | — | EP | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4680304-A | Feed compositions containing 2-(α-pyridyl)-Δ2 -heterocyclic compounds | SMITHKLINE BECKMAN CORPORATION (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| US-4065563-A | 3-Hetero-5-isothiocyanophenyl oxadiazoles as antifungal and antibacterial agents | E. R. SQUIBB & SONS, INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-4022901-A | FUNGICIDAL AND BACTERICIDAL ACTIVITY | E. R. SQUIBB & SONS, INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KDM4E 2853/4885PKM 1304/4885NPC1 72/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KDM4E 2853/4885PKM 1304/4885NPC1 72/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KDM4E 2853/4885PKM 1304/4885NPC1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.